Step 1 of 2
This epidemiologic study characterized early utilization of injectable lenacapavir PrEP in real-world US settings during the first 9 months after FDA approval. Investigators report LEN utilization among a diverse population of individuals, including women, people with no previous PrEP experience, and people with prior oral and injectable PrEP experience.